Device Trial Radar · NCT07757490
Sonablate HIFU International Registry for PC & BPH Patients
Last checked: Nov 21, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Jan 1, 2015
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- SonablateNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Indiana University
- First posted
- Aug 11, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system. This study focuses on adult men who have been treated for localized prostate cancer, benign prostatic hyperplasia (BPH) with urinary symptoms, or a combination of both conditions. The registry collects real-world medical data from multiple clinics globally to better understand how well the HIFU treatment controls disease and affects urinary and sexual function over a 10- to 20-year period. The study includes two groups of participants: a retrospective group of patients who previously received treatment, and a prospective group of newly treated patients receiving standard clinical care. No experimental interventions are assigned for the purpose of this study. To protect participant privacy, all medical data is completely de-identified and stripped of direct identifiers before being securely transferred to the central coordinating center at Indiana University. The ultimate goal of this research is to improve patient care protocols, advance men's health knowledge, and establish evidence-based guidelines for minimally invasive prostate treatments.
Conditions
- Localized Prostate Cancer
- BPH (Benign Prostatic Hyperplasia)
- Prostate Cancer; Benign Prostatic Hyperplasia
Interventions
High Intensity Focused UltrasoundDevice
Use of high intensity focused utrasound and sonatripsy for thermal and mechanical tissue ablation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biochemical and Histological Recurrence-Free Survival RateTime frame: Baseline, and annually up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indiana University Medical Center
Indianapolis, Indiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.